EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Onasemnogene Abeparvovec in Type I Spinal Muscular Atrophy: 24‐Month Follow‐Up From the Italian Registry

Marika Pane, Giorgia Coratti iD, Chiara Cutrì, Antonio Varone, Riccardo Masson, Adele D'Amico iD, Valeria Sansone, Sonia Messina, Federica Ricci, Chiara Ticci, Claudio Bruno, Caterina Agosto und 32 weitere

Annals of Clinical and Translational Neurology · 2026

DOI: 10.1002/acn3.70356 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Annals of Clinical and Translational Neurology, 2026. Verfasst von Marika Pane und 43 weiteren Autor:innen. Beteiligte Einrichtung: Nemo Clinical Center, Fondazione Policlinico Universitario Agostino Gemelli IRCSS, Rome, Italy. Hauptthemen laut MEDLINE: Spinal Muscular Atrophies of Childhood, Genetic Therapy, Outcome Assessment, Health Care. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Biogen, Novartis, Roche Italia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Onasemnogene abeparvovec (OA) is an AAV9‐based gene therapy for spinal muscular atrophy type I (SMA I). Real‐world outcomes show increased response variability compared to clinical trials, and follow‐up data beyond 12–18 months are limited. The aim of this 24‐month prospective observational study is to comprehensively describe the clinical outcomes of an Italian cohort of SMA I patients treated with OA.

Methods

Based on recent literature, patients' treatment status was categorized as: monotherapy (OA only), bridge therapy (transition to OA within 3 months of starting nusinersen or risdiplam), or switch therapy (transition to OA after > 3 months of 1st treatment). Linear mixed‐effects models examined predictors of improvement (CHOP‐INTEND), adjusting for baseline motor function, SMN2 copy number, age, and prior treatment. Descriptive analyses were used to show changes in motor, respiratory, and nutritional milestones.

Results

The cohort included 64 patients: 27 monotherapy, 9 bridge, and 28 switch. All patients showed significant improvement over 24 months ( β = 20.40 points/year, p < 0.001). Patients who switched showed slower improvement ( β = −3.76, p = 0.038) compared to monotherapy, while those who bridged showed no difference. Older age at treatment was associated with slower improvement ( β = −1.48 points/year per month, p = 0.002). Of 49 non‐sitters at baseline, 39 (80%) achieved sitting and 5 (10%) achieved walking. No new safety signals emerged in the second year of follow‐up.

Interpretation

Age and baseline motor functional status significantly influence outcomes; however, substantial confounding, particularly the initial treatment, limits the ability to isolate individual effects. Longer follow‐up is essential for evaluating therapeutic responses in heterogeneous SMA I populations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Spinal Muscular Atrophies of ChildhoodGenetic TherapyOutcome Assessment, Health CareHumansFemaleMaleFollow-Up StudiesChild, PreschoolItalyRegistriesInfantOligonucleotidesGene Therapy AgentsProspective StudiesChildPyrimidinesTreatment OutcomeAzo CompoundsRecombinant Fusion Proteins

Stichwörter der Autor:innen

clinical outcomesgene therapymotor functiononasemnogene abeparvovecspinal muscular atrophy

Substanzen

onasemnogene abeparvovecOligonucleotidesnusinersenPyrimidinesRisdiplamAzo CompoundsRecombinant Fusion Proteins

Autor:innen und Institutionen

  • Nemo Clinical Center, Fondazione Policlinico Universitario Agostino Gemelli IRCSS, Rome, Italy.
  • Pediatric Neurology, Catholic University of the Sacred Heart, Rome, Italy.
  • Pediatric Neurology, Santobono-Pausilipon Children's Hospital, AORN, Naples, Italy.
  • Developmental Neurology Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.
  • Unit of Muscular and Neurodegenerative Disorders, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
  • The NEMO Clinical Center in Milan, Neurorehabilitation Unit, University of Milan, ASST Niguarda Hospital, Milan, Italy.

ORCID-Profile: Giorgia Coratti, Adele D'Amico, Massimiliano Filosto, Michele Tosi

Förderung

  • Biogen
  • Novartis
  • Roche Italia
  • Ministero della Salute
  • Piano Nazionale di Ripresa e Resilienza
  • NextGenerationEU

Zitieren

APA

Pane, M., Coratti, G., Cutrì, C., Varone, A., Masson, R., D'Amico, A., Sansone, V., Messina, S., Ricci, F., Ticci, C., Bruno, C., Agosto, C., Benedetti, F., Pini, A., Siliquini, S., Filosto, M., Zambon, A., Bitetti, I., Manna, M. R., …, & ITASMAC working group (2026). Onasemnogene Abeparvovec in Type I Spinal Muscular Atrophy: 24‐Month Follow‐Up From the Italian Registry. Annals of Clinical and Translational Neurology. https://doi.org/10.1002/acn3.70356

Vancouver

Pane M, Coratti G, Cutrì C, Varone A, Masson R, D'Amico A, et al. Onasemnogene Abeparvovec in Type I Spinal Muscular Atrophy: 24‐Month Follow‐Up From the Italian Registry. Annals of Clinical and Translational Neurology. 2026. doi:10.1002/acn3.70356

BibTeX
@article{Pane2026,
  author = {Pane, Marika and Coratti, Giorgia and Cutrì, Chiara and Varone, Antonio and Masson, Riccardo and D'Amico, Adele and Sansone, Valeria and Messina, Sonia and Ricci, Federica and Ticci, Chiara and Bruno, Claudio and Agosto, Caterina and Benedetti, Francesca and Pini, Antonella and Siliquini, Sabrina and Filosto, Massimiliano and Zambon, Alberto and Bitetti, Ilaria and Manna, Maria Rosaria and Dosi, Claudia and Zanin, Riccardo and Parravicini, Stefano and De Sanctis, Roberto and Stanca, Giulia and Catteruccia, Michela and Tosi, Michele and Mizzoni, Irene and Albamonte, Emilio and Franchino, Valentina and Sframeli, Maria and Cavallina, Ilaria and Procopio, Elena and Sacchini, Michele and Morando, Simone and Brolatti, Noemi and Trucco, Federica and Scarpini, Gaia and Briganti, Elena and Berti, Beatrice and Palermo, Concetta and Leone, Daniela and Previtali, Stefano C and Mercuri, Eugenio and ITASMAC working group, ITASMAC working group},
  title = {Onasemnogene Abeparvovec in Type I Spinal Muscular Atrophy: 24‐Month Follow‐Up From the Italian Registry},
  journal = {Annals of Clinical and Translational Neurology},
  year = {2026},
  doi = {10.1002/acn3.70356}
}
Kostenlos starten →